ClinicalTrials.gg
CompletedNCT06157242Updated May 14, 2025

PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment

A Phase 1 interventional study of Xeruborbactam Oral Prodrug and Ceftibuten in Bacterial Infections, sponsored by Qpex Biopharma, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-14.

Sponsored by Qpex Biopharma, Inc. (part of Shionogi) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Bacterial Infections by Shionogi — none open to participants now, none under way, none of them phase 3. Bacterial Infections · Shionogi.

Started
2024
with 2 others
Phase 1
9 of 10
none open now
Registered
8th of 10
by date

Among the 10 studies in Bacterial Infections by Shionogi, this one is one of 3 that started in 2024, is one of 9 in phase 1, and was the 8th registered.

Bacterial Infections

586 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

None of the 10 studies in Bacterial Infections by Shionogi is open now. The open studies under Bacterial Infections, anywhere →

Where they have run

Who these studies take

Of the 56 Bacterial Infections studies recruiting now, 38 (68%) set no upper age limit and 13 (23%) stop at 75 or younger; 18 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Bacterial Infections by Shionogi as a file.
02

Study summary

A Phase 1, open-label, single-dose study to determine the safety and pharmacokinetics of ORAvance (ceftibuten/xeruborbactam oral prodrug [QPX7831]) in participants with renal impairment

Read the detailed description

Qpex Biopharma, Inc. is developing an oral dosage form that delivers Xeruborbactam, a new boron-based beta-lactamase inhibitor with activity against both serine and metallo-beta-lactamases, for oral treatment in combination with a beta-lactam antibiotic.

Ceftibuten is a cephalosporin antibiotic approved in the US for acute exacerbations of chronic bronchitis, acute bacterial otitis media and pharyngitis/ tonsillitis.

This is a Phase 1 open-label, single-dose study to assess the safety, tolerability, and PK, of ceftibuten and xeruborbactam oral prodrug given in combination to participants with varying degrees of renal impairment as compared to participants with normal renal function.

Objectives:

The objectives of the study are:

  1. To assess the PK of ceftibuten and xeruborbactam oral prodrug given in combination in participants with varying degrees of renal impairment.
  2. To evaluate the safety and tolerability of ceftibuten and xeruborbactam oral prodrug given in combination in participants with varying degrees of renal impairment.
03

Conditions studied

  • Bacterial Infections

Browse trials for

Keywords

  • beta-lactamase inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Participants:

  1. Able to understand the study conduct and tasks required of the participants, sign the form and willing to cooperate with all tests and examinations required by the protocol.
  2. Males and females at least 18 years of age, at the time of consent.
  3. If male, agree to be sexually abstinent or to use 2 approved methods of (refer to Inclusion Criterion #4) when engaging in sexual activity from study check-in through 930 days following the last administration of the study intervention, and to refrain from donating sperm during this same period of time. If the sexual partner is surgically sterile, contraception is not necessary.
  4. Females of must either be sexually abstinent for 14 days prior to day 1 and remain so through 30 days following the last administration of the study intervention, OR have been using (or agree to use) 2 acceptable methods of birth control for the times specified:

    1. Intra-uterine device in place for at least 3 months prior to day 1 through 30 days following the final dosing of the study intervention
    2. Barrier method (condom or diaphragm) for at least 14 days prior to day 1 through 30 days following the final dosing of the study intervention
    3. Stable hormonal contraceptive for at least 3 months prior to day 1 through 30 days following final dosing of the study intervention
    4. Surgical sterilization (vasectomy) of partner at least 6 months prior to day 1
  5. Females of non-childbearing potential must either be (defined as 12 months spontaneous amenorrhea) with a serum follicle stimulating hormone (FSH) level in the laboratory defined postmenopausal range or have undergone 1 of the following sterilization procedures detailed in the study protocol at least 6 months prior to day 1:

    1. Bilateral tubal ligation
    2. Hysterectomy
    3. Hysterectomy with unilateral or bilateral oophorectomy
    4. Bilateral oophorectomy
  6. Have a ≥ 18.5 kg/m2 and ≤ 45 kg/m2, inclusive.
  7. Have sufficient peripheral vascular access, based on the site's assessment, for PK blood sample collection.
  8. Have a semi-recumbent pulse rate ≥ 45 beats per minute (bpm) and ≤ 110 bpm during the vital sign assessment at the screening visit or day -1.
  9. Willing to abstain from alcohol for 48 hours prior to dosing through discharge from the phase 1 unit on day 8.

    Participants With Renal Impairment:

  10. Have an \< 90 mL/min calculated using the CKD-EPI equation adjusted for the participant's BSA and will be calculated using the estimation equation recommended by the FDA. Specifically, group 1, mild renal impairment (eGFR 60 \< 90 mL/min); group 2, moderate renal impairment (eGFR 30 to \< 60 mL/min); and group 3, severe renal impairment (eGFR \< 30 mL/min) not receiving dialysis therapy.
  11. Have negative test results for surface antigen (HBsAg), anti- virus (HCV) antibody and anti- (HIV) antibody. Participants with renal impairment with a positive HCV antibody result will be included at the investigator's discretion if all liver enzyme parameters are within the normal range.

    Participants With Normal Renal Function:

  12. Have an eGFR ≥ 90 mL/min calculated using the CKD-EPI equation adjusted for the participant's BSA.
  13. Have negative test results for HBsAg, anti HCV antibody and anti-HIV antibody.
  14. Meet matching criteria for age, BMI, and gender of pooled renally impaired as defined in the protocol.

Exclusion criteria

Exclusion Criteria:

All Participants:

  1. Have unstable or new medical conditions (eg, cardiovascular, respiratory, hepatic, renal, gastrointestinal, , endocrine, or neurological disorders) which have occurred in the 3 months prior to the first dose of study intervention and which are capable of altering the absorption, distribution, metabolism, or elimination of drugs or, in the opinion of the investigator, constitute a risk factor to participating in the study and/or receiving study intervention.
  2. Documented reaction or anaphylaxis to any antibiotic including ceftibuten or other beta-lactam antibiotics (eg, cephalosporins, penicillins, carbapenems, or monobactams) or any used in this formulation.
  3. History of seizures, head injury, or meningitis.
  4. Current evidence or history of , except squamous cell carcinoma or basal cell carcinoma of the skin, in the 2 years prior to day -1 with no evidence of recurrence.
  5. Females who are pregnant, lactating, or have a positive pregnancy test at the screening visit or day -1.
  6. Previously received any dose of ORAvance (ceftibuten/xeruborbactam oral prodrug), xeruborbactam oral prodrug, xeruborbactam or prodrug alone.
  7. Received any drug within 30 days or 5 half-lives, whichever is longer, prior to day 1 of the current study.
  8. Blood donation or significant blood loss (ie, > 500 mL) within 56 days prior to day 1.
  9. Plasma or donation within 14 days prior to day -1.
  10. Any acute illness requiring antibiotic drug therapy within 30 days prior to day 1 or a febrile illness within 7 days prior to day 1.
  11. Vigorous exercise from 48 hours prior to day -1 until the day of discharge from the study.
  12. Positive drug test at the screening visit or day -1 unless results can be explained by a prescription medication and/or recent history (ie, within 6 months prior to day -1) of abuse of prescription or illicit drugs as detailed in the study protocol.
  13. Positive alcohol test at the screening visit or day -1 and/or recent history (ie, within 6 months prior to day -1) of excessive alcohol intake as defined in the study protocol.

    Excessive intake of alcohol, defined as an average weekly intake of > 14 standard drinks, (standard drink is the equivalent to 120 ml of wine (approximately 12% abv), 350 ml of regular beer (approximately 5% abv), or 45 ml of spirits (40% abv).

  14. Concurrent use of medications known to affect the elimination of serum creatinine and competitors of renal tubular secretion within 30 days prior to the first dose of study intervention or anticipated need for these therapies through the last PK sample.
  15. Employees of the investigative site involved in this study.
  16. Unable or unwilling to adhere to the study-specified procedures and restrictions.
  17. interval > 500 msec, previous history or family history of prolonged QT syndrome at screening or day -1.
  18. Use of products containing caffeine, xanthine, or ephedrine within 24 hours before dosing; the use of alcohol 48 hours prior to dosing; or antacids including calcium carbonate, H2 receptor blockers, and proton pump inhibitors are prohibited 7 days prior to day 1 until the end of the study, including both over-the-counter (OTC) and prescription drugs in these categories.
  19. Have any clinically significant abnormalities in laboratory values at screening or check-in (day -1), defined in the study protocol.
  20. Liver function abnormalities at screening or check-in (day -1) (defined by an elevation in total , (AST), or alanine transaminase (ALT), > for participants based on age and sex).

    Participants With Renal Impairment:

  21. Abnormal and clinically significant findings on physical examination, medical history, serum chemistry, hematology, or urinalysis per investigator discretion. Participants in the renal impairment group will have consideration for the degree of renal impairment and presence of comorbidities.
  22. Have a semi-recumbent systolic BP > 180 or \< 90 mm Hg or have a semi-recumbent diastolic BP > 110 or \< 50 mm Hg at the screening visit or day -1.

    Participants With Normal Renal Function:

  23. Abnormal and clinically significant findings on physical examination, medical history, serum chemistry, hematology, or urinalysis per investigator discretion.
  24. Have a semi-recumbent systolic BP > 150 or \< 90 mm Hg or have a semi-recumbent diastolic BP > 95 or \< 50 mm Hg at the screening visit or day -1.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Open Label, Single Dose Combination of Ceftibuten & Xeruborbactam oral prodrug

    24 pts will be enrolled with varying degrees of RI as well as 8 participants with normal renal function (NRF). 8 participants will be enrolled in each group (G) based on estimated glomerular function rate (eGFR) at screening: * G1: Mild RI (eGFR 60 to 90 mL/min/1.73m2 calculated using the Chronic Kidney Disease Epidemiology Collaboration equation \[CKP-EPI\]) adjusted for the participant's body surface \[BSA\]) * G2: Moderate RI (eGFR 30 to \< 60 mL/min/1.73m2 calculated using the CKD-EPI equation adjusted for the participant's BSA) * G3: Severe RI (eGFR \< 30 mL/min/1.73m2 calculated using the CKD-EPI equation) not receiving dialysis therapy * G4: Healthy participants with NRF matched to patients in Groups 1, 2 and 3 based on age, gender and BMI All pts will receive a single dose of ceftibuten \& QPX7831 on Day 1. Pts will remain in the clinic until completion of the post-dose procedures on Day 8. Participants will be contacted by phone between Days 10-12 for follow-up.

    Drug: Xeruborbactam Oral Prodrug · Drug: Ceftibuten

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent adverse events by subject and by group

    Number of patients with Treatment-Emergent Adverse Events by subject, by group, severity and relationship to treatment

    Time frame: 10 days

  2. Number of patients with changes from baseline in safety parameters

    Number of patients with changes in safety parameters before and after dosing by subject and group

    Time frame: 10 days

  3. Peak plasma Concentration measurements by subject and by group (Cmax)

    Comparison will be performed between the groups for concentration measurements (Cmax). Mean graphical presentation of the data will be reported. Statistical analysis of exposure parameters will be performed.

    Time frame: 10 days

  4. Time concentration data measurements by subject and by group (Tmax)

    Comparison will be performed between the groups for time concentration data measurements (Tmax)

    Time frame: 10 days

  5. Area under the plasma concentration versus time curve (AUC) between groups

    Comparison will be performed between the groups for area under the plasma concentration versus time curve (AUC) Mean graphical presentation of the data will be reported. Statistical analysis of exposure parameters will be performed.

    Time frame: 10 days

  6. Urine Pharmacokinetic (PK) amount excreted by subject and by group

    Urine Pharmacokinetic (PK) parameters such as amount excreted will be calculated from urinary excretion data

    Time frame: 10 days

  7. Urine Pharmacokinetic (PK) % dose excreted by subject and by group

    Urine Pharmacokinetic (PK) parameters such as amount of % dose excreted will be calculated from urinary excretion data

    Time frame: 10 days

07

Study locations

2 sites
  • University of Miami Clinical Pharmacology
    Miami, Florida 33136, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Mar 2025, 4 months.

Of 52 industry-sponsored phase 1 interventional studies under Bacterial Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 4 months is below that.

Counting every sponsor, half of 67 studies reached it within 9 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2023
First posted
Dec 5, 2023
StartActual
Nov 10, 2024
Primary completionActual
Mar 31, 2025
CompletionActual
Mar 31, 2025
Last update
May 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06157242
Collaborators
Shionogi Inc., Biomedical Advanced Research and Development Authority
Responsible party
Sponsor
First posted
Dec 5, 2023
Start date
Nov 10, 2024
Primary completion
Mar 31, 2025
Completion
Mar 31, 2025
Last update
May 14, 2025

Study contacts

Jeff Loutit, MBChB
study director · Qpex Biopharma, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QPX7831

Start the discussion